The TAILOR-PCI study was a multicenter clinical trial initiated by Mayo Clinic that used genetic information to determine the best medication for patients who underwent coronary angioplasty, also known as percutaneous coronary intervention.

TAILOR-PCI, which stands for Tailored Antiplatelet Initiation to Lessen Outcomes Due to Decreased Clopidogrel Response after Percutaneous Coronary Intervention (NCT01742117), has been completed and is no longer open for enrollment. The Mayo Clinic study chair was Naveen L. Pereira, M.D., a cardiologist at Mayo Clinic in Rochester, Minnesota.

For more information about the study, its participants and the results, visit the study page at the Center for Individualized Medicine.